Brand-name Wegovy and Zepbound undergo rigorous testing for purity, potency, sterility, and stability before reaching patients
The TRIUMPH-3 cardiovascular outcomes trial is underway, with results expected in 2027 and that data will be central to full FDA review
The resulting triple mechanism produces weight loss approximately 8 percentage points higher than tirzepatide and 14 percentage points higher than semaglutide
Retatrutide produces more weight loss than semaglutide, and it also produces more adverse events
Our Approach to GLP-1 Management at BW Primary Care Whether your medication is ultimately covered through the Bridge, through commercial insurance, or through a manufacturer cash pay program (NovoCare or LillyDirect), our clinical approach does not change
You can find current trials at ClinicalTrials.gov